Skip to content
Research Article Open access CC BY 4.0

Annexin A2 versus Alpha-Fetoprotein in Diagnosing Hepatocellular Carcinoma: A Diagnostic Meta-Analysis

Erick Thokerunga, Abdullahi Omar Ahmed, Mbasani Rogious

Advances in Research · pp. 1–12 · Published 6 May 2022

10.9734/air/2022/v23i330331

Abstract

Background: Alpha-fetoprotein (AFP) remains widely used for diagnosing hepatocellular carcinoma (HCC) despite its low sensitivity and specificity. Recently, Annexin A2, a highly expressed protein in HCC and almost undetectable in normal liver cells has been studied as a potential alternative. Objective: To synthesize evidence for the diagnostic accuracy of annexin A2 as an alternative to AFP in the diagnosis of hepatocellular carcinoma. Methods: PubMed, Embase, PsycINFO, and the China National Knowledge Infrastructure (chkd-cnki) databases were searched without time constraints up to 2022. Meta-analysis was conducted using Meta-Disc software.  Results: 6 studies were meta-analyzed. The pooled sensitivity and specificity for Annexin A2 were 84% [95% CI :( 80 – 87)], and 78% [95% CI :( 71 – 84)] respectively, while AFP was 70% [95% CI :( 66 – 74)] and 79% [95% CI :( 72 – 85)] respectively. The pooled diagnostic odds ratio was 20.35 [95% CI :( 9.76 – 42.42)] for Annexin A2, and 9.71 [95% CI :( 5.27 – 17.88)] for AFP. The area under the curve (AUC) was 0.88 for Annexin A2 and 0.82 for AFP. Conclusions: Annexin A2 is significantly more sensitive than AFP for HCC diagnosis but less specific. A combination of Annexin A2 and AFP could improve accuracy.  

Annexin A2 alphafeto protein meta-analysis hepatocellular carcinoma

References (27)

  1. 1 Two new Later Stone Age sites from the Final Pleistocene in the Falémé Valley, eastern Senegal [DOI]
  2. 2 Home visits: a strategy to improve newborn survival - Authors' reply [DOI]
  3. 3 Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 [DOI]
  4. 4 EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma [DOI]
  5. 5 Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference [DOI]
  6. 6 The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews [DOI]
  7. 7 Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis [DOI]
  8. 8 Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects [DOI]
  9. 9 Early and Late Recurrence After Liver Resection for Hepatocellular Carcinoma [DOI]
  10. 10 Systematic reviews of evaluations of diagnostic and screening tests
  11. 11 Tumour evolution in hepatocellular carcinoma [DOI]
  12. 12 Early Detection, Curative Treatment, and Survival Rates for Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis: A Meta-analysis [DOI]
  13. 13 Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy [DOI]
  14. 14 Recurrence after liver resection for hepatocellular carcinoma: Risk factors, treatment, and outcomes [DOI]
  15. 15 Test Characteristics of α-Fetoprotein for Detecting Hepatocellular Carcinoma in Patients with Hepatitis C [DOI]
  16. 16 Hepatitis B and C Virus Infection and Hepatocellular Carcinoma in China: A Review of Epidemiology and Control Measures [DOI]
  17. 17 Prognosis of recurrent hepatocellular carcinoma: A 10-year surgical experience in Japan [DOI]
  18. 18 Recurrence of Hepatocellular Carcinoma [DOI]
  19. 19 Effects of adjuvant traditional Chinese medicine therapy on long-term survival in patients with hepatocellular carcinoma [DOI]
  20. 20 Annexin II Binds to Capsid Protein VP1 of Enterovirus 71 and Enhances Viral Infectivity [DOI]
  21. 21 New perspectives and strategy research biomarkers for hepatocellular carcinoma [DOI]
  22. 22 Annexin A2 is a discriminative serological candidate in early hepatocellular carcinoma [DOI]
  23. 23 Evaluation of annexin II as a potential serum marker for hepatocellular carcinoma using a developed sandwich ELISA method [DOI]
  24. 24 Combined Analysis of AFP and HCCR-1 as an Useful Serological Marker for Small Hepatocellular Carcinoma: A Prospective Cohort Study [DOI]
  25. 25 Upregulated expression of Annexin II is a prognostic marker for patients with gastric cancer [DOI]
  26. 26 Expression characteristics and diagnostic value of annexin A2 in hepatocellular carcinoma [DOI]
  27. 27 Screening for hepatocellular carcinoma: summary of current guidelines up to 2018 [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

68

Page views

0

PDF downloads

13

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.